<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138213</url>
  </required_header>
  <id_info>
    <org_study_id>TJDBPS01</org_study_id>
    <nct_id>NCT03138213</nct_id>
  </id_info>
  <brief_title>Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy</brief_title>
  <official_title>Total Laparoscopic Pancreaticoduodenectomy Versus Open Pancreaticoduodenectomy(TJDBPS01) a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Afﬁliated Hospital of North Sichuan Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction Pancreatoduodenectomy (PD) is one of the most complex abdominal operations to
      perform, and it is usually conducted for tumours of the periampullary region and chronic
      pancreatitis. Minimally invasive surgery has been progressively being developed for
      pancreatic surgery, first with the advent of hybrid-laparoscopy and recently with total
      laparoscopic surgery. Issues including the safety and efficacy of total laparoscopic
      pancreaticoduodenectomy (TLPD) and open pancreaticoduodenectomy (OPD) are currently being
      debated. Studies comparing these two surgical techniques are emerging, and large randomized
      controlled trials (RCTs) are lacking but are clearly required.

      Methods and analysis TJDBPS01 is a multicentre, prospective, randomized controlled,
      parallel-group, superiority trial in fourteen centres with pancreatic surgery experts who
      have performed ≥104 TLPDs and OPDs. A total of 656 patients who will undergo PD are randomly
      allocated to the TLPD group or OPD group in a 1:1 ratio. The trial hypothesis is that TLPD
      has superior or equivalent safety and advantages in postoperative recovery compared with OPD.
      The primary outcome is the postoperative length of stay (LOS).

      Ethics and dissemination The Instituitional Review Board Approval of Tongji Hospital, Tongji
      Medical College, Huazhong University of Science and Technology has approved this trial and
      will be routinely monitoring the trial at frequent intervals, as will an independent
      third-party organization. Any results from this trial (publications, conference
      presentations) will be published in peer-reviewed journals and conference proceedings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Length of stay was defined as the postoperative time interval in days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The amount of blood loss during surgical procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time between first incision and last skin closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Mortality was defined as any death that occurred in the 30 days after surgery or during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Clavien-Dindo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCI</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>comprehensive complication index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Overall survival rate for 24 months after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">656</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Surgery</condition>
  <condition>Periampullary Cancer</condition>
  <arm_group>
    <arm_group_label>TLPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ttotal laparoscopic pancreaticoduodenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open pancreaticoduodenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total laparoscopic pancreaticoduodenectomy</intervention_name>
    <description>Total laparoscopic pancreaticoduodenectomy</description>
    <arm_group_label>TLPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open pancreaticoduodenectomy</intervention_name>
    <description>Open pancreaticoduodenectomy</description>
    <arm_group_label>OPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven periampullary cancer, including pancreatic cancer, bile duct
             cancer, duodenal cancer, et al.

          2. Highly presumed malignancy with difficulties to obtain histological evidence.

          3. Preoperative staging work up performed by upper abdomen enhanced CT scan.

          4. The subject understands the nature of this trial and willing to comply.

          5. Ability to provide written informed consent.

          6. Patients treated with curative intent in accordance to international guidelines

        Exclusion Criteria:

          1. Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node
             metastases, involvement of other organs.

          2. Subjects undergoing left, central or total pancreatectomy.

          3. Patients with high operative risk as defined by the American Society of
             Anesthesiologists (ASA) score &gt;4.

          4. Synchronous malignancy in other organs.

          5. Previous underwent pancreatic resections.

          6. Palliative surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hang Zhang, M.D.</last_name>
      <phone>+8613407148260</phone>
      <email>okashiiyo@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>November 24, 2019</last_update_submitted>
  <last_update_submitted_qc>November 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Renyi Qin</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>pancreaticoduodenectomy</keyword>
  <keyword>surgical outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03138213/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03138213/ICF_004.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

